US Patent

US11865098 — Methods and compositions for treating excessive sleepiness

Method of Use · Assigned to Axsome Malta Ltd · Expires 2038-06-01 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using carbamoyl phenylalaninol compounds, specifically solriamfetol hydrochloride, to treat excessive sleepiness in a subject.

USPTO Abstract

The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2548 — solriamfetol-hydrochloride
U-2548 — solriamfetol-hydrochloride

Patent Metadata

Patent number
US11865098
Jurisdiction
US
Classification
Method of Use
Expires
2038-06-01
Drug substance claim
No
Drug product claim
No
Assignee
Axsome Malta Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.